anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Cefotiam
Trial phase: Phase 3
ATC code: J01DC07
SMILES: [H][C@]12SCC(CSc3nnnn3CCN(C)C)=C(C(=O)O)N1C(=O)[C@H]2NC(=O)Cc1csc(N)n1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 111
Group description: Participants received methoxy polyethylene glycol-epoetin beta once monthly by SC injection, for 28 weeks. The initial dose of methoxy polyethylene glycol-epoetin beta was 120 or 200 or 360 µg if the last weekly dose of previous ESA (darbepoetin alfa) was <40 µg or 40-80 µg or >80 µg, respectively. The doses were adjusted according to individual participant's Hb value.
Eligibility criteria:
Inclusion Criteria:

Chronic renal anemia;
Continuous subcutaneous maintenance darbopoetin alfa treatment during previous month;
Hb concentration between 10 and 12 g/dL;
Adequate iron status.

Exclusion Criteria:

Transfusion of red blood cells during previous 2 months;
Significant acute or chronic bleeding, such as overt gastrointestinal bleeding;
Poorly controlled hypertension requiring hospitalization or interruption of darbopoetin alfa treatment in the previous 6 months;
Active malignant disease.
Intervention: Tri-sprintec
Trial phase: Not Applicable
SMILES: C#CC1(O)CCC2C3CCc4cc(O)ccc4C3CCC21C.C#CC1(OC(C)=O)CCC2C3CCC4=CC(=NO)CCC4C3CCC21CC
Sex: Female
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 12
Group description: Trinessa: generic oral contraceptive
Eligibility criteria:
Inclusion Criteria:

nonsmoker
not pregnant
not planning to become pregnant in the next 6 months
not taking hormonal birth control for at least 3 months previous to entering the study
no history of fibroids
no history of ovarian cysts
no history of dysfunctional uterine bleeding

Exclusion Criteria:

pregnant
under the age of 18
over the age of 35
history of irregular uterine bleeding
history of ovarian cysts
history of fibroids
history of migraines with aura
history of liver disease
family or personal history of Blood clots (thromboembolism)
mental disabilities
desire to become pregnant in the next six months
Intervention: Naltrexone
Trial phase: Phase 2
ATC code: A08AA62 | N02AA56 | N07BB04
SMILES: [H][C@@]12Oc3c(O)ccc4c3[C@@]13CCN(CC1CC1)[C@]([H])(C4)[C@]3(O)CCC2=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 25
Group description: Naltrexone

Naltrexone : pill, by mouth, 50mg-150mg/day for the duration of the study
Eligibility criteria:
Inclusion Criteria:

men and women age 18-75;
current DSM-IV trichotillomania;
hair-pulling primarily due to urges/cravings; and 4) pulling is reported as pleasurable the majority of time.

Exclusion Criteria:

unstable medical illness or clinically significant abnormalities on pre-study laboratory tests or physical examination;
history of seizures;
myocardial infarction within 6 months;
current pregnancy or lactation, or inadequate contraception in women of childbearing potential;
clinically significant suicidality;
current or recent (past 3 months) DSM-IV substance abuse or dependence;
illegal substance within 2 weeks of study initiation;
initiation of psychotherapy or behavior therapy from a mental health professional for the treatment of trichotillomania within 3 months prior to study baseline;
initiation of a psychotropic medication within 2 months prior to study inclusion;
previous treatment with naltrexone; and
treatment with investigational medication or depot neuroleptics within 3 months, with fluoxetine within 6 weeks, or with other psychotropics within 2 weeks prior to study baseline;
lifetime history of DSM-IV bipolar disorder type I, dementia, or schizophrenia or any other DSM-IV psychotic disorder;
current use of opiates.
Intervention: Betamethasone
Trial phase: Phase 2
ATC code: A01AC02 | A07EA04 | C05AA05 | C05AA09 | D07AB19 | D07AC01 | D07BC01 | D07CB04 | D07CC01 | D07XB05 | D07XC01 | D10AA03 | H02AB01 | H02AB02 | R01AD03 | R01AD06 | R01AD53 | R03BA04 | S01BA01 | S01BA06 | S01BB04 | S01CA01 | S01CA05 | S01CB01 | S01CB04 | S02BA06 | S02BA07 | S02CA06 | S03BA01 | S03BA03 | S03CA01 | S03CA06
SMILES: CC1CC2C3CCC4=CC(=O)C=CC4(C)C3(F)C(O)CC2(C)C1(O)C(=O)CO
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 44
Group description: 700 µg dexamethasone intravitreal injection at Day 1 in the study eye. Ranibizumab injection at Week 2 or 3 per specified criteria and starting at Week 4 at the investigator's discretion.
Eligibility criteria:
Inclusion Criteria:

50 years of age or older with active subfoveal choroidal neovascularization (CNV) secondary to AMD
Central retinal thickness ≥ 300 µm
Visual acuity between 20/400 and 20/32
Eligible for Anti-VEGF therapy

Exclusion Criteria:

Previous treatment for CNV due to AMD
High eye pressure
Glaucoma
Uncontrolled systemic disease
Known allergy to the study medications
Recent eye surgery or injections in the eye
Female subjects that are of childbearing potential
Intervention: EXENATIDE
Trial phase: Not Applicable
ATC code: A10BJ01
SMILES: CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(N)=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 47
Group description: Exenatide (Byetta®)-5 µg injected subcutaneously twice daily and increased after 1 month to 10 µg twice daily as tolerated by gastrointestinal effects

Exenatide: Exenatide (Byetta®)-5 µg injected subcutaneously twice daily and increased after 1 month to 10 µg twice daily as tolerated by gastrointestinal effects
Eligibility criteria:
Inclusion Criteria:

Male and female patients age 18 to 70 years.
Ability to provide written informed consent
Mentally stable and able to comply with the procedures of the study protocol
Clinical history compatible with impaired fasting glucose or early T2D as defined by a plasma glucose concentration between 110-159 mg/dl following a 12 hour overnight fast performed off any anti-diabetogenic agent for at least 2 weeks (6 weeks for thiazolidinediones)
Stable body weight (+ 5%) for at least 2 weeks
Female Patients: Agree to use adequate contraception if reproductively capable. Adequate contraception includes either a hormonal or barrier method, or surgical sterilization.

Exclusion Criteria:

Diagnosis of type 1 diabetes
Receiving insulin, exenatide (Byetta®), or sitagliptin (Januvia®) treatment or taking > 2 oral anti-diabetogenic agents for the treatment of diabetes
BMI > 44 kg/m2
Allergy to any sulfa-containing compounds
Uncontrolled hypertension (Systolic Blood Pressure >160 or Diastolic Blood Pressure > 100 mmHg)
Uncontrolled hyperlipidemia (triglycerides > 500 or LDL > 160 mg/dl)
Elevation of liver function tests > 2 times the upper limit of normal
Estimated Glomerular Filtration Rate (GFR) < 55 ml/min/1.73m2 (46)
Hyperkalemia (serum potassium > 5.5 mmol/L)
Moderate anemia (hemoglobin concentration < 12 g/dl in men and < 11 g/dl in women)
Female patients: pregnant or lactating
Hepatic cirrhosis
Known active alcohol or substance abuse
Active cardiovascular disease
Use of any investigational agent within 6 weeks of the baseline visit
Any medical condition that, in the opinion of the investigator, will interfere with the safe completion of the trial
Intervention: Sitagliptin
Trial phase: Not Applicable
ATC code: A10BD07 | A10BD12 | A10BD24 | A10BH01 | A10BH51
SMILES: N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 47
Group description: Sitagliptin (Januvia®)-100 mg by mouth every morning

Sitagliptin: Sitagliptin (Januvia®)100 mg by mouth every morning
Eligibility criteria:
Inclusion Criteria:

Male and female patients age 18 to 70 years.
Ability to provide written informed consent
Mentally stable and able to comply with the procedures of the study protocol
Clinical history compatible with impaired fasting glucose or early T2D as defined by a plasma glucose concentration between 110-159 mg/dl following a 12 hour overnight fast performed off any anti-diabetogenic agent for at least 2 weeks (6 weeks for thiazolidinediones)
Stable body weight (+ 5%) for at least 2 weeks
Female Patients: Agree to use adequate contraception if reproductively capable. Adequate contraception includes either a hormonal or barrier method, or surgical sterilization.

Exclusion Criteria:

Diagnosis of type 1 diabetes
Receiving insulin, exenatide (Byetta®), or sitagliptin (Januvia®) treatment or taking > 2 oral anti-diabetogenic agents for the treatment of diabetes
BMI > 44 kg/m2
Allergy to any sulfa-containing compounds
Uncontrolled hypertension (Systolic Blood Pressure >160 or Diastolic Blood Pressure > 100 mmHg)
Uncontrolled hyperlipidemia (triglycerides > 500 or LDL > 160 mg/dl)
Elevation of liver function tests > 2 times the upper limit of normal
Estimated Glomerular Filtration Rate (GFR) < 55 ml/min/1.73m2 (46)
Hyperkalemia (serum potassium > 5.5 mmol/L)
Moderate anemia (hemoglobin concentration < 12 g/dl in men and < 11 g/dl in women)
Female patients: pregnant or lactating
Hepatic cirrhosis
Known active alcohol or substance abuse
Active cardiovascular disease
Use of any investigational agent within 6 weeks of the baseline visit
Any medical condition that, in the opinion of the investigator, will interfere with the safe completion of the trial
Intervention: Glimepiride
Trial phase: Not Applicable
ATC code: A10BB12 | A10BD04 | A10BD06
SMILES: CCC1=C(C)CN(C(=O)NCCc2ccc(S(=O)(=O)NC(=O)N[C@H]3CC[C@H](C)CC3)cc2)C1=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 47
Group description: Glimepiride (Amaryl®)-0.5 mg by mouth every morning and then increased by 0.5 - 1.0 mg at each monthly visit to achieve an average fasting glucose < 110mg/dl

Glimepiride: Glimepiride (Amaryl®)-0.5 mg by mouth every morning and then increased by 0.5 - 1.0 mg at each monthly visit to achieve an average fasting glucose < 110mg/dl
Eligibility criteria:
Inclusion Criteria:

Male and female patients age 18 to 70 years.
Ability to provide written informed consent
Mentally stable and able to comply with the procedures of the study protocol
Clinical history compatible with impaired fasting glucose or early T2D as defined by a plasma glucose concentration between 110-159 mg/dl following a 12 hour overnight fast performed off any anti-diabetogenic agent for at least 2 weeks (6 weeks for thiazolidinediones)
Stable body weight (+ 5%) for at least 2 weeks
Female Patients: Agree to use adequate contraception if reproductively capable. Adequate contraception includes either a hormonal or barrier method, or surgical sterilization.

Exclusion Criteria:

Diagnosis of type 1 diabetes
Receiving insulin, exenatide (Byetta®), or sitagliptin (Januvia®) treatment or taking > 2 oral anti-diabetogenic agents for the treatment of diabetes
BMI > 44 kg/m2
Allergy to any sulfa-containing compounds
Uncontrolled hypertension (Systolic Blood Pressure >160 or Diastolic Blood Pressure > 100 mmHg)
Uncontrolled hyperlipidemia (triglycerides > 500 or LDL > 160 mg/dl)
Elevation of liver function tests > 2 times the upper limit of normal
Estimated Glomerular Filtration Rate (GFR) < 55 ml/min/1.73m2 (46)
Hyperkalemia (serum potassium > 5.5 mmol/L)
Moderate anemia (hemoglobin concentration < 12 g/dl in men and < 11 g/dl in women)
Female patients: pregnant or lactating
Hepatic cirrhosis
Known active alcohol or substance abuse
Active cardiovascular disease
Use of any investigational agent within 6 weeks of the baseline visit
Any medical condition that, in the opinion of the investigator, will interfere with the safe completion of the trial
Intervention: Clindamycin
Trial phase: Phase 3
ATC code: D10AF01 | D10AF51 | G01AA10 | J01FF01
SMILES: [H][C@]1([C@]([H])(NC(=O)[C@@H]2C[C@@H](CCC)CN2C)[C@H](C)Cl)O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O
Sex: All
Age groups: Child | Adult
Healthy volunteers: No
Participants at risk: 328
Group description: Clindamycin gel (containing 1% clindamycin phosphate) applied once daily (in the morning or evening, but at approximately the same time each day) to the entire face for 12 weeks
Eligibility criteria:
Inclusion Criteria:

Be 12 to 45 years of age, inclusive, and in good general health.
Clinical diagnosis of acne vulgaris
Females of childbearing potential participating in the study must agree to use a medically acceptable method of contraception while receiving protocol-assigned product.
Have the ability and willingness to follow all study procedures, attend all scheduled visits, and successfully complete the study.
Have the ability to understand and sign a written informed consent form, which must be completed prior to study specific tasks being performed. Subjects under the legal age of consent in the state/province/country where the study is conducted must provide assent and have the written informed consent of a parent or guardian.

Exclusion Criteria:

Are pregnant or breast-feeding.
Have a history or presence of other conditions that may increase the risk of the subject participating in the study and/or affect the evaluated outcomes.
Used topical antibiotics on the face or used systemic antibiotics within the past 2 weeks.
Used topical corticosteroids on the face or systemic corticosteroids within the past 4 weeks. Use of inhaled, intra-articular, or intra-lesional steroids other than for facial acne is acceptable.
Used systemic retinoids within the past 6 months or topical retinoids within the past 6 weeks.
Received treatment with estrogens (including oral, implanted, injected and topical contraceptives), androgens, or anti-androgenic agents for 12 weeks or less immediately prior to starting study product. Subjects who have been treated with estrogens, as described above, androgens, or anti-androgenic agents for more than 12 consecutive weeks prior to start of study product are allowed to enroll as long as they do not expect to change dose, drug, or discontinue use during the study.
Used topical anti-acne medications (eg, BPO, azelaic acid, resorcinol, salicylates, etc.) within the past 2 weeks.
Used abradents or facial procedures, within the past 2 weeks.
Use medications that may exacerbate acne.
Have a known hypersensitivity or have had previous allergic reaction to any of the active components, lincomycin, or excipients of the study product.
Used any investigational therapy within the past 4 weeks, or currently participating in another clinical study.
Intervention: BENZOYL PEROXIDE
Trial phase: Phase 3
ATC code: D10AE01 | D10AE51
SMILES: O=C(OOC(=O)c1ccccc1)c1ccccc1
Sex: All
Age groups: Child | Adult
Healthy volunteers: No
Participants at risk: 328
Group description: Benzoyl peroxide (BPO) gel (containing 3% benzoyl peroxide) applied once daily (in the morning or evening, but at approximately the same time each day) to the entire face for 12 weeks
Eligibility criteria:
Inclusion Criteria:

Be 12 to 45 years of age, inclusive, and in good general health.
Clinical diagnosis of acne vulgaris
Females of childbearing potential participating in the study must agree to use a medically acceptable method of contraception while receiving protocol-assigned product.
Have the ability and willingness to follow all study procedures, attend all scheduled visits, and successfully complete the study.
Have the ability to understand and sign a written informed consent form, which must be completed prior to study specific tasks being performed. Subjects under the legal age of consent in the state/province/country where the study is conducted must provide assent and have the written informed consent of a parent or guardian.

Exclusion Criteria:

Are pregnant or breast-feeding.
Have a history or presence of other conditions that may increase the risk of the subject participating in the study and/or affect the evaluated outcomes.
Used topical antibiotics on the face or used systemic antibiotics within the past 2 weeks.
Used topical corticosteroids on the face or systemic corticosteroids within the past 4 weeks. Use of inhaled, intra-articular, or intra-lesional steroids other than for facial acne is acceptable.
Used systemic retinoids within the past 6 months or topical retinoids within the past 6 weeks.
Received treatment with estrogens (including oral, implanted, injected and topical contraceptives), androgens, or anti-androgenic agents for 12 weeks or less immediately prior to starting study product. Subjects who have been treated with estrogens, as described above, androgens, or anti-androgenic agents for more than 12 consecutive weeks prior to start of study product are allowed to enroll as long as they do not expect to change dose, drug, or discontinue use during the study.
Used topical anti-acne medications (eg, BPO, azelaic acid, resorcinol, salicylates, etc.) within the past 2 weeks.
Used abradents or facial procedures, within the past 2 weeks.
Use medications that may exacerbate acne.
Have a known hypersensitivity or have had previous allergic reaction to any of the active components, lincomycin, or excipients of the study product.
Used any investigational therapy within the past 4 weeks, or currently participating in another clinical study.
Intervention: Neratinib
Trial phase: Phase 2
ATC code: L01EH02
SMILES: CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 116
Group description: Neratinib

Neratinib: Tablets, 240mg once per day until disease progression or unacceptable toxicity
Eligibility criteria:
Inclusion Criteria:

Stage IIIB, IIIC, or IV erbB2 (HER2) positive breast cancer
Prior use of Herceptin (trastuzumab), and a taxane
Adequate cardiac and renal function

Exclusion Criteria:

More than 2 prior Herceptin (trastuzumab) regimens or prior use of Xeloda (capecitabine) and / or Tykerb (lapatinib) [Tyverb]
Bone as the only site of disease
Active central nervous system metastases (subjects should be stable and off anticonvulsants and steroids)
Significant gastrointestinal disorder with diarrhea as major symptom
Intervention: Biodacyn
Trial phase: Phase 1 | Phase 2
SMILES: NCCC(O)C(=O)NC1CC(N)C(OC2OC(CN)C(O)C(O)C2O)C(O)C1OC1OC(CO)C(O)C(N)C1O.O=S(=O)(O)O.O=S(=O)(O)O
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 21
Group description: Subjects in this cohort will receive 280 mg of ARIKACE™
Eligibility criteria:
Inclusion Criteria:

Written informed consent obtained from patient or designated legal guardian prior to the performance of any study related procedures.
Male or female study subjects ≥6 years of age or older
Confirmed diagnosis of CF
History of chronic infection with P. aeruginosa
Study subjects must produce a screening specimen that is positive for growth of P. aeruginosa
FEV1 ≥ 40% predicted at Screening
SaO2 ≥ 90% at Screening while breathing room air
Ability to comply with study medication use, study visits and study procedures as judged by the investigator
Ability to produce sputum or be willing to undergo an induction to produce sputum for clinical evaluation
Clinically stable with no evidence of acute upper or lower respiratory tract infection of history of pulmonary exacerbation within 4 weeks prior to screening

Key Exclusion Criteria:

Administration of any investigational drug within 8 weeks prior to Screening
Emergency room visit or hospitalization for CF or respiratory-related illness within 4 weeks prior to screening
History of alcohol, medication or illicit drug abuse within the 1 year prior to screening
History of lung transplant
Female of childbearing potential who is lactating or is not practicing an acceptable method of birth control (e.g., abstinence, hormonal or barrier methods, partner sterilization, or IUD)
Positive pregnancy test
Use of any anti-pseudomonal anitbiotics (IV antibiotics, all inhalation antibiotics, oral fluoroquinolones)within the 28 days prior to screening
Initiation of chronic therapy (i.e. TOBI®, high-dose ibuprofen, rhDNase, macrolide antibiotics) within 28 days prior to screening
History of sputum or throat swab culture yielding Burkholderia cepacia within 2 years of Screening
History of mycobacterial or Aspergillus infection
Requiring treatment within 2 years prior to screening, and/or history of allergic bronchopulmonary aspergillosis.
History of biliary cirrhosis with portal hypertension, or splenomegaly
History of daily, continuous oxygen supplementation or requirement for more than 2 L/min at night Change in chest x-ray at screening (or within the 3 months prior to screening)
Intervention: Biodacyn
Trial phase: Phase 1 | Phase 2
SMILES: NCCC(O)C(=O)NC1CC(N)C(OC2OC(CN)C(O)C(O)C2O)C(O)C1OC1OC(CO)C(O)C(N)C1O.O=S(=O)(O)O.O=S(=O)(O)O
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 21
Group description: Subjects in this cohort will receive 560 mg of ARIKACE™
Eligibility criteria:
Inclusion Criteria:

Written informed consent obtained from patient or designated legal guardian prior to the performance of any study related procedures.
Male or female study subjects ≥6 years of age or older
Confirmed diagnosis of CF
History of chronic infection with P. aeruginosa
Study subjects must produce a screening specimen that is positive for growth of P. aeruginosa
FEV1 ≥ 40% predicted at Screening
SaO2 ≥ 90% at Screening while breathing room air
Ability to comply with study medication use, study visits and study procedures as judged by the investigator
Ability to produce sputum or be willing to undergo an induction to produce sputum for clinical evaluation
Clinically stable with no evidence of acute upper or lower respiratory tract infection of history of pulmonary exacerbation within 4 weeks prior to screening

Key Exclusion Criteria:

Administration of any investigational drug within 8 weeks prior to Screening
Emergency room visit or hospitalization for CF or respiratory-related illness within 4 weeks prior to screening
History of alcohol, medication or illicit drug abuse within the 1 year prior to screening
History of lung transplant
Female of childbearing potential who is lactating or is not practicing an acceptable method of birth control (e.g., abstinence, hormonal or barrier methods, partner sterilization, or IUD)
Positive pregnancy test
Use of any anti-pseudomonal anitbiotics (IV antibiotics, all inhalation antibiotics, oral fluoroquinolones)within the 28 days prior to screening
Initiation of chronic therapy (i.e. TOBI®, high-dose ibuprofen, rhDNase, macrolide antibiotics) within 28 days prior to screening
History of sputum or throat swab culture yielding Burkholderia cepacia within 2 years of Screening
History of mycobacterial or Aspergillus infection
Requiring treatment within 2 years prior to screening, and/or history of allergic bronchopulmonary aspergillosis.
History of biliary cirrhosis with portal hypertension, or splenomegaly
History of daily, continuous oxygen supplementation or requirement for more than 2 L/min at night Change in chest x-ray at screening (or within the 3 months prior to screening)
Intervention: LEVONORGESTREL
Trial phase: Phase 3
ATC code: G03AA07 | G03AB03 | G03AC03 | G03AD01 | G03FA11 | G03FB09
SMILES: [H][C@@]12CCC3=CC(=O)CC[C@]3([H])[C@@]1([H])CC[C@@]1(CC)[C@@]2([H])CC[C@@]1(O)C#C
Sex: Female
Age groups: Child
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 299
Group description: One tablet for emergency contraception
Eligibility criteria:
Inclusion Criteria:

Female and 11-16 years of age, inclusive
Subject must be requesting emergency contraception for her own use (not for use by another person) and for current (not future) use
Subject can read and understand English, according to her own judgment
Others as dictated by FDA-approved protocol